Press Releases Year None202420232022202120202019 Oct 23, 2024 Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial Oct 14, 2024 Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor Sep 30, 2024 Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting Sep 23, 2024 Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers Sep 13, 2024 Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024 Aug 28, 2024 Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio Aug 27, 2024 Repare Therapeutics to Participate in Two Upcoming Investor Conferences Aug 06, 2024 Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results Jun 26, 2024 Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI Jun 10, 2024 Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 23